Ensifentrine

A dual inhibitor of phosphodiesterase 3 and 4

Ensifentrine
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Ensifentrine is a novel bronchodilator and anti-inflammatory agent that is being investigated for the treatment of chronic obstructive pulmonary disease (COPD) and other respiratory conditions. It is a dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4), which are enzymes involved in the regulation of intracellular levels of cyclic adenosine monophosphate (cAMP).

Mechanism of Action

Ensifentrine works by inhibiting the activity of PDE3 and PDE4, leading to an increase in intracellular cAMP levels. This results in relaxation of the airway smooth muscle, providing a bronchodilatory effect, and also reduces inflammation in the airways. The dual inhibition of PDE3 and PDE4 is thought to provide a synergistic effect, enhancing both bronchodilation and anti-inflammatory actions.

Clinical Development

Ensifentrine is currently undergoing clinical trials to evaluate its efficacy and safety in patients with COPD. Early studies have shown that it can improve lung function and reduce symptoms in patients with moderate to severe COPD. The drug is administered via inhalation, which allows for direct delivery to the lungs and minimizes systemic exposure.

Potential Benefits

The dual action of ensifentrine as both a bronchodilator and anti-inflammatory agent makes it a promising candidate for the treatment of COPD, a condition characterized by chronic inflammation and airflow limitation. By targeting both aspects of the disease, ensifentrine may offer improved symptom control and quality of life for patients.

Side Effects

As with any medication, ensifentrine may cause side effects. Common side effects observed in clinical trials include headache, cough, and throat irritation. The safety profile of ensifentrine is still being evaluated in ongoing studies.

Related Pages

• Chronic obstructive pulmonary disease
• Bronchodilator
• Phosphodiesterase inhibitor
• Cyclic adenosine monophosphate